No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer.
Ovarian Cancer Association Consortium, Breast Cancer Association Consortium, and Consortium of Modifiers of BRCA1 and BRCA2 None., Hollestelle A., van der Baan FH., Berchuck A., Johnatty SE., Aben KK., Agnarsson BA., Aittomäki K., Alducci E., Andrulis IL., Anton-Culver H., Antonenkova NN., Antoniou AC., Apicella C., Arndt V., Arnold N., Arun BK., Arver B., Ashworth A., Australian Ovarian Cancer Study Group None., Baglietto L., Balleine R., Bandera EV., Barrowdale D., Bean YT., Beckmann L., Beckmann MW., Benitez J., Berger A., Berger R., Beuselinck B., Bisogna M., Bjorge L., Blomqvist C., Bogdanova NV., Bojesen A., Bojesen SE., Bolla MK., Bonanni B., Brand JS., Brauch H., Breast Cancer Family Register None., Brenner H., Brinton L., Brooks-Wilson A., Bruinsma F., Brunet J., Brüning T., Budzilowska A., Bunker CH., Burwinkel B., Butzow R., Buys SS., Caligo MA., Campbell I., Carter J., Chang-Claude J., Chanock SJ., Claes KBM., Collée JM., Cook LS., Couch FJ., Cox A., Cramer D., Cross SS., Cunningham JM., Cybulski C., Czene K., Damiola F., Dansonka-Mieszkowska A., Darabi H., de la Hoya M., deFazio A., Dennis J., Devilee P., Dicks EM., Diez O., Doherty JA., Domchek SM., Dorfling CM., Dörk T., Silva IDS., du Bois A., Dumont M., Dunning AM., Duran M., Easton DF., Eccles D., Edwards RP., Ehrencrona H., Ejlertsen B., Ekici AB., Ellis SD., EMBRACE None., Engel C., Eriksson M., Fasching PA., Feliubadalo L., Figueroa J., Flesch-Janys D., Fletcher O., Fontaine A., Fortuzzi S., Fostira F., Fridley BL., Friebel T., Friedman E., Friel G., Frost D., Garber J., García-Closas M., Gayther SA., GEMO Study Collaborators None., GENICA Network None., Gentry-Maharaj A., Gerdes A-M., Giles GG., Glasspool R., Glendon G., Godwin AK., Goodman MT., Gore M., Greene MH., Grip M., Gronwald J., Gschwantler Kaulich D., Guénel P., Guzman SR., Haeberle L., Haiman CA., Hall P., Halverson SL., Hamann U., Hansen TVO., Harter P., Hartikainen JM., Healey S., HEBON None., Hein A., Heitz F., Henderson BE., Herzog J., T Hildebrandt MA., Høgdall CK., Høgdall E., Hogervorst FBL., Hopper JL., Humphreys K., Huzarski T., Imyanitov EN., Isaacs C., Jakubowska A., Janavicius R., Jaworska K., Jensen A., Jensen UB., Johnson N., Jukkola-Vuorinen A., Kabisch M., Karlan BY., Kataja V., Kauff N., KConFab Investigators None., Kelemen LE., Kerin MJ., Kiemeney LA., Kjaer SK., Knight JA., Knol-Bout JP., Konstantopoulou I., Kosma V-M., Krakstad C., Kristensen V., Kuchenbaecker KB., Kupryjanczyk J., Laitman Y., Lambrechts D., Lambrechts S., Larson MC., Lasa A., Laurent-Puig P., Lazaro C., Le ND., Le Marchand L., Leminen A., Lester J., Levine DA., Li J., Liang D., Lindblom A., Lindor N., Lissowska J., Long J., Lu KH., Lubinski J., Lundvall L., Lurie G., Mai PL., Mannermaa A., Margolin S., Mariette F., Marme F., Martens JWM., Massuger LFAG., Maugard C., Mazoyer S., McGuffog L., McGuire V., McLean C., McNeish I., Meindl A., Menegaux F., Menéndez P., Menkiszak J., Menon U., Mensenkamp AR., Miller N., Milne RL., Modugno F., Montagna M., Moysich KB., Müller H., Mulligan AM., Muranen TA., Narod SA., Nathanson KL., Ness RB., Neuhausen SL., Nevanlinna H., Neven P., Nielsen FC., Nielsen SF., Nordestgaard BG., Nussbaum RL., Odunsi K., Offit K., Olah E., Olopade OI., Olson JE., Olson SH., Oosterwijk JC., Orlow I., Orr N., Orsulic S., Osorio A., Ottini L., Paul J., Pearce CL., Pedersen IS., Peissel B., Pejovic T., Pelttari LM., Perkins J., Permuth-Wey J., Peterlongo P., Peto J., Phelan CM., Phillips K-A., Piedmonte M., Pike MC., Platte R., Plisiecka-Halasa J., Poole EM., Poppe B., Pylkäs K., Radice P., Ramus SJ., Rebbeck TR., Reed MWR., Rennert G., Risch HA., Robson M., Rodriguez GC., Romero A., Rossing MA., Rothstein JH., Rudolph A., Runnebaum I., Salani R., Salvesen HB., Sawyer EJ., Schildkraut JM., Schmidt MK., Schmutzler RK., Schneeweiss A., Schoemaker MJ., Schrauder MG., Schumacher F., Schwaab I., Scuvera G., Sellers TA., Severi G., Seynaeve CM., Shah M., Shrubsole M., Siddiqui N., Sieh W., Simard J., Singer CF., Sinilnikova OM., Smeets D., Sohn C., Soller M., Song H., Soucy P., Southey MC., Stegmaier C., Stoppa-Lyonnet D., Sucheston L., SWE-BRCA None., Swerdlow A., Tangen IL., Tea M-K., Teixeira MR., Terry KL., Terry MB., Thomassen M., Thompson PJ., Tihomirova L., Tischkowitz M., Toland AE., Tollenaar RAEM., Tomlinson I., Torres D., Truong T., Tsimiklis H., Tung N., Tworoger SS., Tyrer JP., Vachon CM., Van 't Veer LJ., van Altena AM., Van Asperen CJ., van den Berg D., van den Ouweland AMW., van Doorn HC., Van Nieuwenhuysen E., van Rensburg EJ., Vergote I., Verhoef S., Vierkant RA., Vijai J., Vitonis AF., von Wachenfeldt A., Walsh C., Wang Q., Wang-Gohrke S., Wappenschmidt B., Weischer M., Weitzel JN., Weltens C., Wentzensen N., Whittemore AS., Wilkens LR., Winqvist R., Wu AH., Wu X., Yang HP., Zaffaroni D., Pilar Zamora M., Zheng W., Ziogas A., Chenevix-Trench G., Pharoah PDP., Rookus MA., Hooning MJ., Goode EL.
OBJECTIVE: Clinical genetic testing is commercially available for rs61764370, an inherited variant residing in a KRAS 3' UTR microRNA binding site, based on suggested associations with increased ovarian and breast cancer risk as well as with survival time. However, prior studies, emphasizing particular subgroups, were relatively small. Therefore, we comprehensively evaluated ovarian and breast cancer risks as well as clinical outcome associated with rs61764370. METHODS: Centralized genotyping and analysis were performed for 140,012 women enrolled in the Ovarian Cancer Association Consortium (15,357 ovarian cancer patients; 30,816 controls), the Breast Cancer Association Consortium (33,530 breast cancer patients; 37,640 controls), and the Consortium of Modifiers of BRCA1 and BRCA2 (14,765 BRCA1 and 7904 BRCA2 mutation carriers). RESULTS: We found no association with risk of ovarian cancer (OR=0.99, 95% CI 0.94-1.04, p=0.74) or breast cancer (OR=0.98, 95% CI 0.94-1.01, p=0.19) and results were consistent among mutation carriers (BRCA1, ovarian cancer HR=1.09, 95% CI 0.97-1.23, p=0.14, breast cancer HR=1.04, 95% CI 0.97-1.12, p=0.27; BRCA2, ovarian cancer HR=0.89, 95% CI 0.71-1.13, p=0.34, breast cancer HR=1.06, 95% CI 0.94-1.19, p=0.35). Null results were also obtained for associations with overall survival following ovarian cancer (HR=0.94, 95% CI 0.83-1.07, p=0.38), breast cancer (HR=0.96, 95% CI 0.87-1.06, p=0.38), and all other previously-reported associations. CONCLUSIONS: rs61764370 is not associated with risk of ovarian or breast cancer nor with clinical outcome for patients with these cancers. Therefore, genotyping this variant has no clinical utility related to the prediction or management of these cancers.